Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Sell
29
AGNG Quote, Financials, Valuation and Earnings
Last price:
$30.32
Seasonality move
:
1.65%
Day range:
$30.10 - $30.38
52-week range:
$28.00 - $33.64
Dividend yield:
0.82%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
3.4K
Avg. volume:
4.9K
1-year change:
5.92%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AGNG
Global X Aging Population ETF
|
$30.42 | -- | -- | -- | $0.15 | 0.82% | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
$10.18 | -- | -- | -- | $0.00 | 0% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$10.29 | -- | -- | -- | $0.00 | 0% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$29.67 | -- | -- | -- | $0.00 | 0% | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$51.91 | -- | -- | -- | $0.33 | 5.43% | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$22.70 | -- | -- | -- | $0.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AGNG
Global X Aging Population ETF
|
-- | 1.018 | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | 1.617 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.174 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.470 | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 0.988 | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
Global X Aging Population ETF vs. Competitors
-
Which has Higher Returns AGNG or EDOC?
Global X Telemedicine & Digital Health ETF has a net margin of -- compared to Global X Aging Population ETF's net margin of --. Global X Aging Population ETF's return on equity of -- beat Global X Telemedicine & Digital Health ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGNGGlobal X Aging Population ETF-- -- -- EDOCGlobal X Telemedicine & Digital Health ETF-- -- -- -
What do Analysts Say About AGNG or EDOC?
Global X Aging Population ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Telemedicine & Digital Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Aging Population ETF has higher upside potential than Global X Telemedicine & Digital Health ETF, analysts believe Global X Aging Population ETF is more attractive than Global X Telemedicine & Digital Health ETF.
Company Buy Ratings Hold Ratings Sell Ratings AGNGGlobal X Aging Population ETF0 0 0 EDOCGlobal X Telemedicine & Digital Health ETF0 0 0 -
Is AGNG or EDOC More Risky?
Global X Aging Population ETF has a beta of 0.780, which suggesting that the stock is 21.991% less volatile than S&P 500. In comparison Global X Telemedicine & Digital Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AGNG or EDOC?
Global X Aging Population ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 0.82%. Global X Telemedicine & Digital Health ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global X Aging Population ETF pays -- of its earnings as a dividend. Global X Telemedicine & Digital Health ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGNG or EDOC?
Global X Aging Population ETF quarterly revenues are --, which are smaller than Global X Telemedicine & Digital Health ETF quarterly revenues of --. Global X Aging Population ETF's net income of -- is lower than Global X Telemedicine & Digital Health ETF's net income of --. Notably, Global X Aging Population ETF's price-to-earnings ratio is -- while Global X Telemedicine & Digital Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Aging Population ETF is -- versus -- for Global X Telemedicine & Digital Health ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGNGGlobal X Aging Population ETF-- -- -- -- EDOCGlobal X Telemedicine & Digital Health ETF-- -- -- --
-
Which has Higher Returns AGNG or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to Global X Aging Population ETF's net margin of --. Global X Aging Population ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGNGGlobal X Aging Population ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About AGNG or GNOM?
Global X Aging Population ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Aging Population ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe Global X Aging Population ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings AGNGGlobal X Aging Population ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is AGNG or GNOM More Risky?
Global X Aging Population ETF has a beta of 0.780, which suggesting that the stock is 21.991% less volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.142, suggesting its more volatile than the S&P 500 by 14.178%.
-
Which is a Better Dividend Stock AGNG or GNOM?
Global X Aging Population ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 0.82%. Global X Genomics & Biotechnology ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global X Aging Population ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGNG or GNOM?
Global X Aging Population ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. Global X Aging Population ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, Global X Aging Population ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Aging Population ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGNGGlobal X Aging Population ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns AGNG or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to Global X Aging Population ETF's net margin of --. Global X Aging Population ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGNGGlobal X Aging Population ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About AGNG or HTEC?
Global X Aging Population ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Aging Population ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe Global X Aging Population ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings AGNGGlobal X Aging Population ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is AGNG or HTEC More Risky?
Global X Aging Population ETF has a beta of 0.780, which suggesting that the stock is 21.991% less volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.075, suggesting its more volatile than the S&P 500 by 7.497%.
-
Which is a Better Dividend Stock AGNG or HTEC?
Global X Aging Population ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 0.82%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global X Aging Population ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGNG or HTEC?
Global X Aging Population ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. Global X Aging Population ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, Global X Aging Population ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Aging Population ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGNGGlobal X Aging Population ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns AGNG or JDOC?
JPMorgan Healthcare Leaders ETF has a net margin of -- compared to Global X Aging Population ETF's net margin of --. Global X Aging Population ETF's return on equity of -- beat JPMorgan Healthcare Leaders ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGNGGlobal X Aging Population ETF-- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- -
What do Analysts Say About AGNG or JDOC?
Global X Aging Population ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand JPMorgan Healthcare Leaders ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Aging Population ETF has higher upside potential than JPMorgan Healthcare Leaders ETF, analysts believe Global X Aging Population ETF is more attractive than JPMorgan Healthcare Leaders ETF.
Company Buy Ratings Hold Ratings Sell Ratings AGNGGlobal X Aging Population ETF0 0 0 JDOCJPMorgan Healthcare Leaders ETF0 0 0 -
Is AGNG or JDOC More Risky?
Global X Aging Population ETF has a beta of 0.780, which suggesting that the stock is 21.991% less volatile than S&P 500. In comparison JPMorgan Healthcare Leaders ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AGNG or JDOC?
Global X Aging Population ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 0.82%. JPMorgan Healthcare Leaders ETF offers a yield of 5.43% to investors and pays a quarterly dividend of $0.33 per share. Global X Aging Population ETF pays -- of its earnings as a dividend. JPMorgan Healthcare Leaders ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGNG or JDOC?
Global X Aging Population ETF quarterly revenues are --, which are smaller than JPMorgan Healthcare Leaders ETF quarterly revenues of --. Global X Aging Population ETF's net income of -- is lower than JPMorgan Healthcare Leaders ETF's net income of --. Notably, Global X Aging Population ETF's price-to-earnings ratio is -- while JPMorgan Healthcare Leaders ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Aging Population ETF is -- versus -- for JPMorgan Healthcare Leaders ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGNGGlobal X Aging Population ETF-- -- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- --
-
Which has Higher Returns AGNG or THNR?
Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to Global X Aging Population ETF's net margin of --. Global X Aging Population ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AGNGGlobal X Aging Population ETF-- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -
What do Analysts Say About AGNG or THNR?
Global X Aging Population ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Aging Population ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe Global X Aging Population ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.
Company Buy Ratings Hold Ratings Sell Ratings AGNGGlobal X Aging Population ETF0 0 0 THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 -
Is AGNG or THNR More Risky?
Global X Aging Population ETF has a beta of 0.780, which suggesting that the stock is 21.991% less volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AGNG or THNR?
Global X Aging Population ETF has a quarterly dividend of $0.15 per share corresponding to a yield of 0.82%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.36 per share. Global X Aging Population ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AGNG or THNR?
Global X Aging Population ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. Global X Aging Population ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, Global X Aging Population ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Aging Population ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AGNGGlobal X Aging Population ETF-- -- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is General Electric Stock Going Up?
General Electric Company, doing business these days as GE Aerospace…
Where Will Cisco Systems Stock Be in 10 Years?
Cisco Systems, Inc. (NASDAQ:CSCO) has enjoyed its position as a…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
1
IONQ alert for Jan 9
IonQ [IONQ] is down 38.82% over the past day.
Sell
40
QMCO alert for Jan 9
Quantum [QMCO] is down 30.08% over the past day.
Sell
47
MATW alert for Jan 9
Matthews International [MATW] is up 14.21% over the past day.
